const L124 = [
  {
    "id": 1,
    "category": "Aminoglycosides: PK/Clinical Use",
    "questionText": "A 60-year-old male with liver cirrhosis presents with confusion and asterixis, consistent with hepatic encephalopathy. The physician prescribes oral neomycin. Why is the *oral* formulation of this highly toxic antibiotic used for this specific condition?",
    "options": [
      {"text": "It is absorbed from the GI tract and metabolized by the healthy liver.", "explanation": "This is incorrect. Neomycin is not absorbed from the GI tract, which is the entire basis for its oral use."},
      {"text": "It is not absorbed from the GI tract and acts locally to eliminate ammonia-producing bacteria.", "explanation": "This is correct. Oral neomycin is not absorbed and is used to eliminate ammonia-producing bacteria in the gut, thereby reducing the ammonia load that contributes to hepatic encephalopathy."},
      {"text": "It binds irreversibly to the 16S rRNA of human gut cells.", "explanation": "This is incorrect. It targets bacterial ribosomes, not human cells."},
      {"text": "It is a prodrug that is converted to gentamicin in the gut.", "explanation": "This is incorrect. Neomycin is its own active drug, not a prodrug."},
      {"text": "It is less nephrotoxic when given orally compared to IV.", "explanation": "This is incorrect. It's not given orally because it's *less* toxic, but because it is *not absorbed* and thus avoids systemic toxicity altogether while achieving a local effect."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0011.jpg"
  },
  {
    "id": 2,
    "category": "Aminoglycosides: Pharmacokinetics",
    "questionText": "A 70-year-old male is being treated with gentamicin for a gram-negative infection. His renal function begins to decline, and his serum creatinine rises from 1.0 mg/dL to 2.5 mg/dL. How will this change in renal function affect the pharmacokinetics of gentamicin?",
    "options": [
      {"text": "The drug's half-life will significantly shorten.", "explanation": "This is incorrect. A decrease in renal function will decrease clearance and *prolong* the half-life."},
      {"text": "The drug will be eliminated via biliary excretion instead.", "explanation": "This is incorrect. Aminoglycosides are not eliminated via the biliary system."},
      {"text": "The drug's half-life will significantly lengthen, requiring dose adjustment.", "explanation": "This is correct. Aminoglycosides are excreted as active drug via glomerular filtration, so clearance is proportional to creatinine clearance. Renal impairment will dramatically increase the half-life from 2-3 hours to 24-48 hours, necessitating dose adjustment."},
      {"text": "It will have no effect, as the drug is metabolized by the liver.", "explanation": "This is incorrect. Aminoglycosides are not metabolized."},
      {"text": "It will increase the drug's oral bioavailability.", "explanation": "This is incorrect. Aminoglycosides are not given orally for systemic infections as they are not absorbed."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0016.jpg"
  },
  {
    "id": 3,
    "category": "Aminoglycosides: Pharmacokinetics",
    "questionText": "A 65-year-old female with septic shock and significant anasarca (fluid overload) requires treatment with an aminoglycoside. How will this patient's fluid status likely alter the volume of distribution (Vd) for this class of drugs?",
    "options": [
      {"text": "The Vd will decrease, requiring a lower dose.", "explanation": "This is incorrect. The Vd will increase because the drug distributes in extracellular fluid."},
      {"text": "The Vd will increase, requiring a higher dose.", "explanation": "This is correct. Aminoglycosides distribute in body water/extracellular fluid. In patients with edema or fluid overload, the Vd is increased, which may necessitate a higher loading dose."},
      {"text": "The Vd will be unchanged, as the drug is protein-bound.", "explanation": "This is incorrect. The drug has minor plasma protein binding and its Vd is highly dependent on fluid status."},
      {"text": "The drug will be trapped in the inner ear, decreasing Vd.", "explanation": "This is incorrect. While it does accumulate in the inner ear, this doesn't decrease the overall Vd in a fluid-overloaded patient."},
      {"text": "The drug will be unable to leave the plasma, decreasing Vd.", "explanation": "This is incorrect. The drug is polar but distributes well in the extracellular fluid."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0016.jpg"
  },
  {
    "id": 4,
    "category": "Aminoglycosides: Pharmacokinetics/Toxicity",
    "questionText": "The major toxicities of aminoglycosides (nephrotoxicity and ototoxicity) are directly related to their pharmacokinetic property of accumulating in high concentrations within which two specific locations?",
    "options": [
      {"text": "Renal tubular cells and endolymph/perilymph of the inner ear", "explanation": "This is correct. Aminoglycosides are actively taken up and accumulate in the proximal renal tubular cells and the endolymph/perilymph, leading to cellular damage and toxicity in these organs."},
      {"text": "Adipose tissue and the central nervous system", "explanation": "This is incorrect. As polar, water-soluble drugs, they have poor penetration into adipose tissue and the CNS."},
      {"text": "Bile and the gastrointestinal lumen", "explanation": "This is incorrect. They are cleared renally, not via bile, and are not absorbed from the GI lumen."},
      {"text": "Pulmonary surfactant and skin", "explanation": "This is incorrect. Inactivation by pulmonary surfactant is characteristic of daptomycin, not aminoglycosides."},
      {"text": "Red blood cells and bone marrow", "explanation": "This is incorrect. Bone marrow suppression is not a characteristic toxicity of this class."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L124_page-0016.jpg"
  },
  {
    "id": 5,
    "category": "Aminoglycosides: Pharmacodynamics",
    "questionText": "A 40-year-old male is being treated for a severe *P. aeruginosa* infection. The pharmacist recommends a high-dose, extended-interval (once-daily) dosing strategy for the aminoglycoside. What is the primary rationale for this approach?",
    "options": [
      {"text": "It is less expensive and easier for nursing staff.", "explanation": "This is incorrect. While it may be easier, the primary reason is pharmacodynamic and toxicity-related."},
      {"text": "It maintains a T>MIC, which is optimal for this class.", "explanation": "This is incorrect. T>MIC is the driver for beta-lactams; aminoglycosides are concentration-dependent."},
      {"text": "It maximizes concentration-dependent killing and is associated with *less* nephrotoxicity.", "explanation": "This is correct. This strategy achieves a high Cmax/MIC, maximizing concentration-dependent killing, and allows a long trough period, which is associated with *less* nephrotoxicity than divided-dose regimens."},
      {"text": "It is the only way to overcome enzymatic inactivation.", "explanation": "This is incorrect. This dosing does not overcome transferase enzyme resistance."},
      {"text": "It prevents the drug from crossing the placenta.", "explanation": "This is incorrect. Dosing strategy does not prevent the drug from crossing the placenta."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0019.jpg"
  },
  {
    "id": 6,
    "category": "Aminoglycosides: Dosing/Synergy",
    "questionText": "A 55-year-old male is diagnosed with infective endocarditis caused by *Enterococcus faecalis*. The treatment plan includes ampicillin plus low-dose, divided-interval (e.g., every 8 hours) gentamicin. Why is this specific dosing regimen used for this indication?",
    "options": [
      {"text": "This regimen is used for all gram-positive infections.", "explanation": "This is incorrect. This specific regimen is an exception, not the rule."},
      {"text": "High-dose, extended-interval dosing is ineffective against *Enterococcus*.", "explanation": "This is incorrect. The rationale is for synergy, and this is the traditional, proven method for it."},
      {"text": "This regimen is *more* nephrotoxic but required for synergy.", "explanation": "This is incorrect. This regimen is an exception to the 'high-dose is less nephrotoxic' rule; it is used for achieving synergy, not because it's more toxic."},
      {"text": "Once-daily dosing is not used for infective endocarditis synergy.", "explanation": "This is correct. High-dose, extended-interval dosing is the preferred method for most indications, but *not* for the treatment of infective endocarditis, where traditional, lower-dose, divided-interval dosing is still used for synergy."},
      {"text": "This regimen is required to achieve a high Cmax/MIC.", "explanation": "This is incorrect. This regimen results in a *lower* Cmax (peak) than once-daily dosing."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L124_page-0023.jpg"
  },
  {
    "id": 7,
    "category": "Aminoglycosides: Pharmacodynamics",
    "questionText": "The bactericidal activity of aminoglycosides increases as the drug concentration rises significantly above the MIC. This property, which is the basis for high-dose, extended-interval dosing, is known as:",
    "options": [
      {"text": "Time-dependent killing", "explanation": "This is incorrect. This describes beta-lactams, where efficacy is driven by time above the MIC, not the height of the peak."},
      {"text": "Post-antibiotic effect (PAE)", "explanation": "This is incorrect. PAE is the *persistent* effect after the drug falls below the MIC, not the killing action related to the peak concentration."},
      {"text": "Concentration-dependent killing", "explanation": "This is correct. Aminoglycosides exhibit concentration-dependent killing, where the rate and extent of bacterial killing increase with higher drug concentrations (i.e., a higher Cmax/MIC ratio)."},
      {"text": "Bacteriostatic activity", "explanation": "This is incorrect. Aminoglycosides are bactericidal."},
      {"text": "Synergistic killing", "explanation": "This is incorrect. Synergy describes the interaction of two drugs, not the intrinsic PD property of a single drug."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0018.jpg"
  },
  {
    "id": 8,
    "category": "Aminoglycosides: Pharmacodynamics",
    "questionText": "A patient is receiving once-daily gentamicin. The drug's concentration is measured and found to be below the MIC for 8 hours of the 24-hour dosing interval. However, bacterial growth remains suppressed. This phenomenon, which supports extended-interval dosing, is called:",
    "options": [
      {"text": "Prolonged persistent effects (Post-antibiotic effect)", "explanation": "This is correct. Aminoglycosides exhibit a prolonged post-antibiotic effect (PAE), where antibacterial activity persists for several hours *after* the drug concentration falls below the MIC."},
      {"text": "Concentration-dependent killing", "explanation": "This is incorrect. This refers to the rate of killing at high concentrations, not the persistent effect after the concentration drops."},
      {"text": "Intrinsic resistance", "explanation": "This is incorrect. This would imply the drug isn't working at all."},
      {"text": "Toxicity threshold", "explanation": "This is incorrect. This is the level above which adverse effects are more likely, not a measure of efficacy."},
      {"text": "Bacteriostatic suppression", "explanation": "This is incorrect. While it is suppression, the specific term for this persistent effect is PAE."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L124_page-0018.jpg"
  },
  {
    "id": 9,
    "category": "Aminoglycosides: Pharmacodynamics",
    "questionText": "A 50-year-old male with diabetes has a large, purulent abscess. The abscess is drained, and the pH of the purulent material is measured at 6.0. How does this acidic environment affect the activity of an aminoglycoside like gentamicin?",
    "options": [
      {"text": "It significantly enhances activity.", "explanation": "This is incorrect. Aminoglycosides are less active in acidic environments."},
      {"text": "It significantly reduces activity.", "explanation": "This is correct. Aminoglycosides are polycationic molecules that are more active at alkaline pH. An acidic environment (low pH) impairs their activity."},
      {"text": "It has no effect on activity.", "explanation": "This is incorrect. pH is a critical factor for aminoglycoside activity."},
      {"text": "It converts the drug from bactericidal to bacteriostatic.", "explanation": "This is incorrect. It simply reduces its overall bactericidal efficacy."},
      {"text": "It prevents the drug from causing nephrotoxicity.", "explanation": "This is incorrect. The local pH of an abscess does not affect the systemic risk of nephrotoxicity."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0015.jpg"
  },
  {
    "id": 10,
    "category": "Aminoglycosides: Mechanism of Action",
    "questionText": "An aminoglycoside enters a gram-negative bacterium and exerts its bactericidal effect. It does this by binding *irreversibly* to which specific target within the bacterial ribosome?",
    "options": [
      {"text": "The 23S rRNA of the 50S subunit", "explanation": "This is incorrect. This is the location of the peptidyl transferase center, the target for macrolides and chloramphenicol."},
      {"text": "The 16S rRNA of the 30S subunit", "explanation": "This is correct. Aminoglycosides bind irreversibly to the 16S rRNA component of the 30S ribosomal subunit."},
      {"text": "The 50S subunit's exit tunnel", "explanation": "This is incorrect. This is a target for macrolides."},
      {"text": "DNA gyrase (Topoisomerase II)", "explanation": "This is incorrect. This is the target of fluoroquinolones."},
      {"text": "Penicillin-binding proteins (PBPs)", "explanation": "This is incorrect. This is the target of beta-lactam antibiotics."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0020.jpg"
  },
  {
    "id": 11,
    "category": "Aminoglycosides: Mechanism of Action",
    "questionText": "A gram-negative bacterium, *E. coli*, is exposed to gentamicin. The drug crosses the outer membrane via porins. What is the next step for its entry into the cytoplasm, which also explains why this drug is ineffective against anaerobes?",
    "options": [
      {"text": "Passive diffusion across the lipid bilayer", "explanation": "This is incorrect. As a polar molecule, it cannot passively diffuse across the lipid membrane."},
      {"text": "Oxygen-dependent active transport across the cytoplasmic membrane", "explanation": "This is correct. Aminoglycosides are actively transported across the inner cytoplasmic membrane by an oxygen-dependent mechanism. This is why they are ineffective against anaerobes, which lack this system."},
      {"text": "Binding to D-Ala-D-Ala on the membrane", "explanation": "This is incorrect. This describes vancomycin's mechanism of action."},
      {"text": "Uptake via the bacterial iron transport system", "explanation": "This is incorrect. This describes the unique entry mechanism of cefiderocol."},
      {"text": "Disruption of the membrane, causing potassium efflux", "explanation": "This is incorrect. This describes the mechanism of daptomycin."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0009.jpg"
  },
  {
    "id": 12,
    "category": "Aminoglycosides: Mechanism of Action (Synergy)",
    "questionText": "A patient with *Enterococcus faecalis* endocarditis is treated with ampicillin and gentamicin. What is the rationale for adding gentamicin to the ampicillin regimen?",
    "options": [
      {"text": "Gentamicin covers anaerobic bacteria that ampicillin misses.", "explanation": "This is incorrect. Gentamicin is *not* active against anaerobes."},
      {"text": "Ampicillin inhibits the transferase enzymes that inactivate gentamicin.", "explanation": "This is incorrect. Ampicillin does not inhibit these enzymes."},
      {"text": "Gentamicin inhibits the beta-lactamase enzymes that inactivate ampicillin.", "explanation": "This is incorrect. Gentamicin is not a beta-lactamase inhibitor."},
      {"text": "Ampicillin damages the cell wall, enhancing gentamicin's penetration to the ribosome.", "explanation": "This is correct. Aminoglycosides poorly penetrate the thick cell wall of gram-positives. A cell wall inhibitor (like ampicillin) damages the wall, enhancing penetration and providing a synergistic bactericidal effect."},
      {"text": "Both drugs are needed to cause misreading of the mRNA.", "explanation": "This is incorrect. Only gentamicin causes misreading; ampicillin inhibits cell wall synthesis."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L124_page-0015.jpg"
  },
  {
    "id": 13,
    "category": "Aminoglycosides: Mechanism of Action",
    "questionText": "Once bound to the 30S ribosome, aminoglycosides are believed to have at least three distinct mechanisms of inhibiting protein synthesis. Which mechanism involves disrupting the assembly of the 70S ribosome from its subunits?",
    "options": [
      {"text": "Blocking the initiation complex", "explanation": "This is correct. One of the three recognized mechanisms is that aminoglycosides interfere with the initiation complex, which inhibits the assembly of the functional ribosomal apparatus."},
      {"text": "Blocking translocation on the mRNA", "explanation": "This is incorrect. This is a separate, distinct mechanism of aminoglycosides."},
      {"text": "Causing misreading of the mRNA", "explanation": "This is incorrect. This is also a separate, distinct mechanism of aminoglycosides."},
      {"text": "Inhibiting peptidyl transferase", "explanation": "This is incorrect. This is the action of 50S inhibitors like chloramphenicol, not aminoglycosides."},
      {"text": "Preventing tRNA from binding to the A-site", "explanation": "This is incorrect. This is the mechanism of tetracyclines."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L124_page-0020.jpg"
  },
  {
    "id": 14,
    "category": "Aminoglycosides: Mechanism of Action",
    "questionText": "A scientist observes that when an aminoglycoside is added to a bacterial culture, the bacteria begin to produce abnormal, nonfunctional proteins. This is due to which unique mechanism of action for this drug class?",
    "options": [
      {"text": "Blocking the initiation complex", "explanation": "This is incorrect. Blocking the initiation complex would prevent protein synthesis from starting, not create abnormal proteins."},
      {"text": "Blocking translocation", "explanation": "This is incorrect. This would halt protein synthesis, not create abnormal proteins."},
      {"text": "Misreading of the mRNA and incorporation of incorrect amino acids", "explanation": "This is correct. A key mechanism of aminoglycosides is to cause misreading of the mRNA, which leads to the incorporation of incorrect amino acids and the production of abnormal or nonfunctional proteins."},
      {"text": "Inhibiting the 50S peptidyl transferase center", "explanation": "This is incorrect. This would halt peptide bond formation, not cause misreading."},
      {"text": "Binding irreversibly to DNA gyrase", "explanation": "This is incorrect. This describes fluoroquinolones."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0020.jpg"
  },
  {
    "id": 15,
    "category": "Spectinomycin: Board Review",
    "questionText": "A 28-year-old patient has a *Neisseria gonorrhoeae* infection that is resistant to ceftriaxone. Although not available in the US, which alternative IM drug (an aminocyclitol) works by binding the 30S subunit but does *not* cause misreading of mRNA?",
    "options": [
      {"text": "Gentamicin", "explanation": "This is incorrect. Gentamicin is an aminoglycoside and *does* cause misreading."},
      {"text": "Amikacin", "explanation": "This is incorrect. Amikacin is an aminoglycoside and *does* cause misreading."},
      {"text": "Spectinomycin", "explanation": "This is correct. Spectinomycin is an aminocyclitol (not an AG) used almost exclusively for drug-resistant gonorrhea. It binds the 30S subunit but does not cause misreading, and there is no cross-resistance."},
      {"text": "Streptomycin", "explanation": "This is incorrect. Streptomycin is an aminoglycoside and *does* cause misreading."},
      {"text": "Daptomycin", "explanation": "This is incorrect. Daptomycin targets the cell membrane, not the ribosome."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0013.jpg"
  },
  {
    "id": 16,
    "category": "Aminoglycosides: MOA",
    "questionText": "While most protein synthesis inhibitors (e.g., tetracyclines, macrolides) are bacteriostatic, aminoglycosides are bactericidal. This is primarily because they bind in what way to the ribosome?",
    "options": [
      {"text": "Reversibly to the 50S subunit", "explanation": "This is incorrect. They bind to the 30S subunit, and their binding is irreversible."},
      {"text": "Irreversibly to the 30S subunit", "explanation": "This is correct. Aminoglycosides bind irreversibly to the 30S ribosome, leading to a bactericidal effect, whereas most other protein synthesis inhibitors bind reversibly and are bacteriostatic."},
      {"text": "Reversibly to the 30S subunit", "explanation": "This is incorrect. This describes tetracyclines."},
      {"text": "By competing with calcium", "explanation": "This is incorrect. This relates to their neuromuscular blockade adverse effect, not their bactericidal MOA."},
      {"text": "By chelating iron", "explanation": "This is incorrect. This describes cefiderocol's entry mechanism."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0007.jpg"
  },
  {
    "id": 17,
    "category": "Aminoglycosides: Spectrum (Resistance)",
    "questionText": "A 52-year-old male has an intra-abdominal abscess. Cultures grow *Bacteroides fragilis*. The physician knows that aminoglycosides are *not* effective for this infection. What is the mechanism of this intrinsic resistance?",
    "options": [
      {"text": "*B. fragilis* produces transferase enzymes.", "explanation": "This is incorrect. This is an *acquired* resistance mechanism, not the reason for *intrinsic* resistance in all anaerobes."},
      {"text": "*B. fragilis* lacks the oxygen-dependent active transport mechanism.", "explanation": "This is correct. Anaerobic bacteria (and facultative anaerobes in anaerobic environments) are intrinsically resistant because they lack the oxygen-dependent transport system required to move the aminoglycoside across the cytoplasmic membrane."},
      {"text": "*B. fragilis* has an altered 16S rRNA target site.", "explanation": "This is incorrect. This is a rare acquired resistance mechanism, not the basis for intrinsic anaerobic resistance."},
      {"text": "*B. fragilis* has a cell wall that is impermeable to aminoglycosides.", "explanation": "This is incorrect. This is a partial reason for poor G+ activity, not for G- anaerobe resistance."},
      {"text": "*B. fragilis* is an atypical bacterium without a cell wall.", "explanation": "This is incorrect. *B. fragilis* is a gram-negative anaerobe with a cell wall."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0022.jpg"
  },
  {
    "id": 18,
    "category": "Aminoglycosides: Spectrum of Activity",
    "questionText": "A patient is started on an aminoglycoside. This class of antibiotics provides excellent coverage for which of the following types of organisms?",
    "options": [
      {"text": "Aerobic gram-negative bacilli", "explanation": "This is correct. The primary spectrum of activity for aminoglycosides is aerobic gram-negative bacteria, including Enterobacterales and *Pseudomonas*."},
      {"text": "Atypical bacteria (e.g., *Mycoplasma*)", "explanation": "This is incorrect. Aminoglycosides, like beta-lactams, are ineffective against atypicals."},
      {"text": "Obligate anaerobes (e.g., *C. difficile*)", "explanation": "This is incorrect. They are intrinsically resistant due to the lack of oxygen-dependent transport."},
      {"text": "Fungi (e.g., *Candida albicans*)", "explanation": "This is incorrect. Aminoglycosides are antibacterial, not antifungal."},
      {"text": "Gram-positive cocci (as monotherapy)", "explanation": "This is incorrect. They are not reliably effective when used *alone* (as monotherapy) for gram-positive infections due to poor penetration of the thick cell wall."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L124_page-0022.jpg"
  },
  {
    "id": 19,
    "category": "Aminoglycosides: Resistance",
    "questionText": "A hospital's antibiogram shows high rates of gentamicin resistance among *Klebsiella pneumoniae* isolates. What is the *principal mechanism* by which these gram-negative bacteria acquire resistance to aminoglycosides?",
    "options": [
      {"text": "Modification of the PBP target site", "explanation": "This is incorrect. This is the mechanism of beta-lactam resistance."},
      {"text": "Expression of drug-inactivating transferase enzymes", "explanation": "This is correct. The principal mechanism of acquired resistance is the production of transferase enzymes (acetyl-, phospho-, or adenyltransferases) that modify and inactivate the drug."},
      {"text": "Modification of the binding target to D-Ala-D-Lactate", "explanation": "This is incorrect. This is the mechanism of vancomycin resistance in VRE."},
      {"text": "Mutation of the 16S rRNA binding site", "explanation": "This is incorrect. This is an uncommon mechanism, except notably for streptomycin resistance in *M. tuberculosis*."},
      {"text": "Complete deletion of the 30S ribosome", "explanation": "This is incorrect. This would be lethal to the bacterium."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0022.jpg"
  },
  {
    "id": 20,
    "category": "Aminoglycosides: Resistance",
    "questionText": "A patient has multidrug-resistant tuberculosis (MDR-TB). The organism is found to be resistant to streptomycin. This specific resistance is most commonly due to which of the following mechanisms?",
    "options": [
      {"text": "Production of a transferase enzyme", "explanation": "This is incorrect. While this is the main mechanism for GNBs, it is not the primary mechanism for streptomycin resistance in TB."},
      {"text": "Alteration or deletion of ribosomal receptor protein (target alteration)", "explanation": "This is correct. Alteration (mutation) of the 30S ribosomal binding site is the primary mechanism of *M. tuberculosis* resistance to streptomycin."},
      {"text": "Impaired drug entry via porin deletion", "explanation": "This is incorrect. This is another possible mechanism, but target alteration is the primary one cited for this specific bug-drug pair."},
      {"text": "Lack of an oxygen-dependent transport system", "explanation": "This is incorrect. *M. tuberculosis* is an obligate aerobe."},
      {"text": "Inactivation by lung surfactant", "explanation": "This is incorrect. This describes daptomycin."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0022.jpg"
  },
  {
    "id": 21,
    "category": "Aminoglycosides: Clinical Use (Resistance)",
    "questionText": "A patient in the ICU has a ventilator-associated pneumonia (VAP) caused by a gram-negative rod that is resistant to both gentamicin and tobramycin. Which other aminoglycoside is specifically noted to be active against many gentamicin- and tobramycin-resistant strains?",
    "options": [
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is too toxic for parenteral use and is not used for VAP."},
      {"text": "Streptomycin", "explanation": "This is incorrect. Streptomycin resistance is widespread, and it is not typically used for these types of GNB infections."},
      {"text": "Amikacin", "explanation": "This is correct. Amikacin (and plazomicin) is active against many strains that are resistant to gentamicin and tobramycin, often due to its structure being less susceptible to transferase enzymes."},
      {"text": "Paromomycin", "explanation": "This is incorrect. Paromomycin is used for parasitic infections."},
      {"text": "Spectinomycin", "explanation": "This is incorrect. Spectinomycin is not an aminoglycoside and is used for gonorrhea."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0024.jpg"
  },
  {
    "id": 22,
    "category": "Aminoglycosides: Clinical Use (Comparison)",
    "questionText": "A physician is choosing between gentamicin and tobramycin for an empiric VAP regimen. While they have comparable activity, tobramycin is often preferred if *Pseudomonas aeruginosa* is strongly suspected. Why?",
    "options": [
      {"text": "Tobramycin is the only one active against *P. aeruginosa*.", "explanation": "This is incorrect. Gentamicin is also active, but tobramycin is slightly more so."},
      {"text": "Tobramycin is slightly more active than gentamicin against *P. aeruginosa*.", "explanation": "This is correct. While both are active, tobramycin is noted to be slightly more active than gentamicin against *P. aeruginosa*."},
      {"text": "Tobramycin is not nephrotoxic, unlike gentamicin.", "explanation": "This is incorrect. All aminoglycosides share the same class toxicities, including nephrotoxicity."},
      {"text": "Gentamicin is only active against gram-positive bacteria.", "explanation": "This is incorrect. Gentamicin's primary spectrum is aerobic gram-negative bacteria."},
      {"text": "Tobramycin can be given orally.", "explanation": "This is incorrect. It is not given orally for systemic infections; it is available for inhalation, but not oral use."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0024.jpg"
  },
  {
    "id": 23,
    "category": "Aminoglycosides: Clinical Use (Synergy)",
    "questionText": "A 60-year-old male with a prosthetic heart valve is diagnosed with infective endocarditis. This is a serious gram-positive infection. What is the primary reason an aminoglycoside (like gentamicin) is added to a cell wall inhibitor (like ampicillin or vancomycin)?",
    "options": [
      {"text": "To cover aerobic gram-negative bacilli", "explanation": "This is incorrect. While AGs do cover GNBs, the target in endocarditis is gram-positive, and the AG is added for synergy, not spectrum expansion."},
      {"text": "To provide enhanced uptake and synergy", "explanation": "This is correct. For serious gram-positive infections like endocarditis, an aminoglycoside is added to a cell wall inhibitor for its synergistic effect and to enhance the penetration of the AG into the bacterium."},
      {"text": "To prevent ototoxicity from the cell wall inhibitor", "explanation": "This is incorrect. The AG *causes* ototoxicity; it does not prevent it."},
      {"text": "To treat a co-infection with *M. tuberculosis*", "explanation": "This is incorrect. This is not the standard indication for endocarditis therapy."},
      {"text": "To overcome anaerobic resistance", "explanation": "This is incorrect. Aminoglycosides are not active against anaerobes."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0023.jpg"
  },
  {
    "id": 24,
    "category": "Aminoglycosides: Clinical Use (Streptomycin)",
    "questionText": "A 30-year-old park ranger presents with high fever, chills, and a painful, swollen lymph node (a bubo) in his groin. He reports recently handling a dead rodent. This presentation is classic for plague (*Yersinia pestis*). Which aminoglycoside is a first-line treatment for this zoonotic infection?",
    "options": [
      {"text": "Amikacin", "explanation": "This is incorrect. Amikacin is typically reserved for resistant GNBs or MDR-TB."},
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is topical only."},
      {"text": "Tobramycin", "explanation": "This is incorrect. Tobramycin is primarily used for *P. aeruginosa*."},
      {"text": "Streptomycin", "explanation": "This is correct. Streptomycin (and gentamicin) is a treatment of choice for the zoonotic infections plague and tularemia."},
      {"text": "Paromomycin", "explanation": "This is incorrect. This is for parasitic infections."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L124_page-0024.jpg"
  },
  {
    "id": 25,
    "category": "Aminoglycosides: Clinical Use (Streptomycin)",
    "questionText": "A 45-year-old hunter presents with an ulcer on his hand, fever, and tender axillary lymphadenopathy. He reports skinning a rabbit 3 days ago. This presentation is consistent with tularemia. Which aminoglycoside is a primary treatment for this condition?",
    "options": [
      {"text": "Streptomycin", "explanation": "This is correct. Streptomycin (and gentamicin) is a treatment of choice for the zoonotic infections tularemia and plague."},
      {"text": "Amikacin", "explanation": "This is incorrect. This is not the first-line agent for tularemia."},
      {"text": "Plazomicin", "explanation": "This is incorrect. This is a last-line agent for cUTI."},
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is topical only."},
      {"text": "Tobramycin", "explanation": "This is incorrect. This is not the first-line agent for tularemia."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L124_page-0B024.jpg"
  },
  {
    "id": 26,
    "category": "Aminoglycosides: Clinical Use (Neomycin)",
    "questionText": "A patient is scheduled for elective bowel surgery. To reduce the risk of post-operative infection, the surgeon prescribes oral neomycin combined with erythromycin. What is the purpose of oral neomycin in this setting?",
    "options": [
      {"text": "To provide systemic coverage against gram-negative bacteria.", "explanation": "This is incorrect. Oral neomycin is not absorbed and cannot provide systemic coverage."},
      {"text": "To treat a *C. difficile* infection caused by the erythromycin.", "explanation": "This is incorrect. Oral vancomycin or fidaxomicin is used for *C. difficile*, not neomycin."},
      {"text": "To act locally in the GI tract to reduce bowel flora.", "explanation": "This is correct. Oral neomycin is not absorbed and is approved for bowel sterilization prior to elective surgery, acting locally to reduce ammonia-producing or pathogenic bacteria in the gut."},
      {"text": "To prevent ototoxicity from the erythromycin.", "explanation": "This is incorrect. Both can be ototoxic, though neomycin's risk is systemic, which is avoided here."},
      {"text": "To treat a co-existing parasitic infection.", "explanation": "This is incorrect. That is the indication for paromomycin."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0024.jpg"
  },
  {
    "id": 27,
    "category": "Aminoglycosides: Clinical Use (Tobramycin)",
    "questionText": "A 15-year-old patient with cystic fibrosis has a chronic cough and sputum cultures persistently positive for *P. aeruginosa*. Which aminoglycoside is available in an inhalation formulation specifically to treat this condition?",
    "options": [
      {"text": "Gentamicin", "explanation": "This is incorrect. Gentamicin is not typically formulated for inhalation for this purpose."},
      {"text": "Tobramycin", "explanation": "This is correct. Tobramycin is available as an oral inhalation product used to manage chronic *P. aeruginosa* lung infections in patients with cystic fibrosis."},
      {"text": "Amikacin", "explanation": "This is incorrect. While amikacin has *P. aeruginosa* activity, tobramycin is the agent specifically mentioned for this formulation and use."},
      {"text": "Streptomycin", "explanation": "This is incorrect. Streptomycin is not used for *P. aeruginosa*."},
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is topical only and not used for this."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0024.jpg"
  },
  {
    "id": 28,
    "category": "Aminoglycosides: Clinical Use",
    "questionText": "A 35-year-old immigrant presents with a 2-month history of cough, hemoptysis, fever, and night sweats. A chest X-ray shows apical cavities. Sputum is positive for acid-fast bacilli, and cultures confirm multidrug-resistant tuberculosis (MDR-TB). Which of the following aminoglycosides are options for this condition?",
    "options": [
      {"text": "Gentamicin and Tobramycin", "explanation": "This is incorrect. These are not typically first-line agents for MDR-TB."},
      {"text": "Amikacin and Streptomycin", "explanation": "This is correct. Amikacin and Streptomycin are both used as part of combination therapy for drug-resistant tuberculosis."},
      {"text": "Neomycin and Paromomycin", "explanation": "This is incorrect. These agents are not used for TB."},
      {"text": "Plazomicin and Gentamicin", "explanation": "This is incorrect. Plazomicin is not indicated for TB."},
      {"text": "Tobramycin and Plazomicin", "explanation": "This is incorrect. These are not the primary AGs used for MDR-TB."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0024.jpg"
  },
  {
    "id": 29,
    "category": "Aminoglycosides: Clinical Use",
    "questionText": "A 68-year-old female with a history of recurrent UTIs presents with fever, flank pain, and dysuria. Urine culture grows a multidrug-resistant *E. coli* that is resistant to carbapenems and cephalosporins. Which of the newest aminoglycosides is approved as a last-line agent for complicated UTIs caused by MDR GNBs?",
    "options": [
      {"text": "Streptomycin", "explanation": "This is incorrect. Streptomycin resistance is common, and it's not used for this."},
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is not used systemically."},
      {"text": "Plazomicin", "explanation": "This is correct. Plazomicin is a next-generation aminoglycoside engineered to evade many transferase enzymes and is approved for complicated UTIs in patients with limited options."},
      {"text": "Tobramycin", "explanation": "This is incorrect. The organism is MDR, and Plazomicin is the specific agent for this 'last-line' scenario."},
      {"text": "Paromomycin", "explanation": "This is incorrect. This is for parasitic infections."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0024.jpg"
  },
  {
    "id": 30,
    "category": "Aminoglycosides: Clinical Use",
    "questionText": "A 25-year-old male returns from a trip abroad with abdominal cramping and diarrhea. A stool sample reveals *Entamoeba histolytica* cysts. Which aminoglycoside is given *orally* to act luminally for the treatment of intestinal amoebiasis?",
    "options": [
      {"text": "Gentamicin", "explanation": "This is incorrect. Gentamicin is not used for amoebiasis."},
      {"text": "Streptomycin", "explanation": "This is incorrect. Streptomycin is not used for amoebiasis."},
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is used orally for bowel prep or hepatic encephalopathy, not amoebiasis."},
      {"text": "Paromomycin", "explanation": "This is correct. Oral paromomycin is not absorbed and acts as a luminal agent for the treatment of intestinal amoebiasis."},
      {"text": "Amikacin", "explanation": "This is incorrect. Amikacin is not used for amoebiasis."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L124_page-0011.jpg"
  },
  {
    "id": 31,
    "category": "Aminoglycosides: Adverse Effects",
    "questionText": "A 72-year-old male on day 7 of gentamicin therapy for bacteremia has a serum creatinine that has risen from 0.9 mg/dL to 2.1 mg/dL. This nephrotoxicity is a result of the drug accumulating in, and causing damage to, which part of the nephron?",
    "options": [
      {"text": "The glomerulus", "explanation": "This is incorrect. While glomerular dysfunction is a result, the primary site of accumulation and damage is the tubule."},
      {"text": "The proximal tubular cells", "explanation": "This is correct. Aminoglycosides accumulate in the proximal renal tubular cells, leading to progressive tubular cell damage and dysfunction, which then manifests as a rise in serum creatinine."},
      {"text": "The loop of Henle", "explanation": "This is incorrect. This is the primary site of action for loop diuretics."},
      {"text": "The collecting duct", "explanation": "This is incorrect. This is a site of action for ADH and other diuretics."},
      {"text": "The afferent arteriole", "explanation": "This is incorrect. This is a site of action for NSAIDs, not the site of AG accumulation."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0026.jpg"
  },
  {
    "id": 32,
    "category": "Aminoglycosides: Adverse Effects",
    "questionText": "A 68-year-old female develops acute kidney injury (AKI) while on tobramycin. The drug is discontinued, and her serum creatinine slowly returns to baseline over the next two weeks. This recovery is possible because of which feature of aminoglycoside nephrotoxicity?",
    "options": [
      {"text": "The nephrotoxicity is often reversible as proximal tubular cells can regenerate.", "explanation": "This is correct. Unlike ototoxicity, aminoglycoside-induced nephrotoxicity is often reversible because the proximal tubular cells have the capacity to regenerate after the toxic insult is removed."},
      {"text": "The nephrotoxicity is a non-immune reaction that resolves with antihistamines.", "explanation": "This is incorrect. This describes 'Red Man Syndrome' from vancomycin, not nephrotoxicity."},
      {"text": "The drug's half-life is only 2 hours, so it clears immediately.", "explanation": "This is incorrect. The half-life is 2-3 hours in *normal* renal function; in AKI, the half-life is dramatically prolonged."},
      {"text": "The damage is to the glomerulus, which is not permanent.", "explanation": "This is incorrect. The primary damage is to the tubules, not the glomerulus, and glomerular damage can be permanent."},
      {"text": "The nephrotoxicity is actually caused by a disulfiram-like reaction.", "explanation": "This is incorrect. This has no relation to a disulfiram reaction."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L124_page-0026.jpg"
  },
  {
    "id": 33,
    "category": "Aminoglycosides: Adverse Effects",
    "questionText": "A 50-year-old male on a 10-day course of amikacin for a resistant infection reports a new-onset headache, dizziness, and a feeling that the room is spinning (vertigo). He also struggles to walk in a straight line. These symptoms are most consistent with:",
    "options": [
      {"text": "Nephrotoxicity", "explanation": "This is incorrect. Nephrotoxicity would present as a rising serum creatinine, not neurologic symptoms."},
      {"text": "Cochlear toxicity", "explanation": "This is incorrect. Cochlear toxicity would present with tinnitus and hearing loss."},
      {"text": "Vestibular toxicity", "explanation": "This is correct. Aminoglycoside ototoxicity can manifest as vestibular toxicity, which damages the labyrinthine sensory cells, causing symptoms like vertigo, ataxia (loss of balance), and nystagmus."},
      {"text": "Neuromuscular blockade", "explanation": "This is incorrect. This would present as muscle weakness and respiratory paralysis, not vertigo."},
      {"text": "Peripheral neuritis", "explanation": "This is incorrect. This is a specific toxicity of streptomycin, presenting with paresthesias."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0027.jpg"
  },
  {
    "id": 34,
    "category": "Aminoglycosides: Adverse Effects",
    "questionText": "A 62-year-old female on gentamicin reports a new ringing in her ears (tinnitus) and notices she has difficulty hearing high-pitched sounds. An audiogram confirms high-frequency hearing loss. This is a manifestation of which aminoglycoside toxicity?",
    "options": [
      {"text": "Nephrotoxicity", "explanation": "This is incorrect. Nephrotoxicity affects the kidneys."},
      {"text": "Vestibular toxicity", "explanation": "This is incorrect. Vestibular toxicity affects balance and presents with vertigo."},
      {"text": "Cochlear toxicity", "explanation": "This is correct. Aminoglycoside ototoxicity can manifest as cochlear toxicity, which presents with tinnitus and high-frequency hearing loss due to the degeneration of hair cells in the cochlea."},
      {"text": "Scotoma", "explanation": "This is incorrect. This is a blind spot, an optic nerve toxicity associated with streptomycin."},
      {"text": "Allergic dermatitis", "explanation": "This is incorrect. This is a hypersensitivity reaction, most common with topical neomycin."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0027.jpg"
  },
  {
    "id": 35,
    "category": "Aminoglycosides: Adverse Effects",
    "questionText": "A 70-year-old man who received a 14-day course of amikacin for a resistant infection reports that his hearing loss and vertigo have persisted 6 months after discontinuing the drug. What is the reason for the permanence of this adverse effect?",
    "options": [
      {"text": "The drug is permanently stored in adipose tissue.", "explanation": "This is incorrect. The drug is water-soluble and does not store in fat."},
      {"text": "The drug causes irreversible destruction of vestibular and cochlear sensory cells.", "explanation": "This is correct. Ototoxicity is a major concern because the drug's accumulation in the inner ear leads to the progressive destruction of sensory (hair) cells, which do not regenerate. This can result in irreversible hearing loss."},
      {"text": "The drug causes a reversible renal tubular acidosis.", "explanation": "This is incorrect. The renal damage is tubular *damage*, not acidosis, and it is often reversible, unlike ototoxicity."},
      {"text": "The patient also consumed alcohol, causing a disulfiram-like reaction.", "explanation": "This is incorrect. This is not related to ototoxicity."},
      {"text": "The drug causes a curare-like effect at the NMJ.", "explanation": "This is incorrect. This describes neuromuscular blockade, which is a separate, acute toxicity."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0027.jpg"
  },
  {
    "id": 36,
    "category": "Aminoglycosides: Cautions/Adverse Effects",
    "questionText": "A 65-year-old female with myasthenia gravis is in the ICU for septic shock. The team is considering an empiric regimen that includes an aminoglycoside. Why must this drug class be avoided or used with extreme caution in this patient?",
    "options": [
      {"text": "It has a high risk of causing 'Red Man Syndrome'.", "explanation": "This is incorrect. This is an adverse effect of vancomycin."},
      {"text": "It can exacerbate muscle weakness and cause respiratory depression.", "explanation": "This is correct. Aminoglycosides can cause neuromuscular blockade. In a patient with myasthenia gravis, who already has muscle weakness, this can be exacerbated and lead to respiratory depression or paralysis."},
      {"text": "It will interfere with her pyridostigmine therapy.", "explanation": "This is incorrect. The interaction is pharmacodynamic at the NMJ, not a metabolic interaction with her medication."},
      {"text": "Patients with myasthenia gravis cannot clear the drug.", "explanation": "This is incorrect. Drug clearance is renal; the contraindication is pharmacodynamic."},
      {"text": "It causes irreversible cochlear toxicity in all myasthenia gravis patients.", "explanation": "This is incorrect. The primary *contraindication* is neuromuscular blockade, not ototoxicity, although that is also a risk."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0030.jpg"
  },
  {
    "id": 37,
    "category": "Aminoglycosides: Adverse Effects (MOA)",
    "questionText": "A patient undergoing surgery receives a high intrapleural dose of an aminoglycoside and subsequently develops respiratory paralysis. This neuromuscular blockade is caused by the aminoglycoside's 'curare-like effect,' which involves which two mechanisms?",
    "options": [
      {"text": "Inhibiting acetylcholinesterase and stimulating nicotinic receptors", "explanation": "This is incorrect. This would *increase* stimulation, not cause blockade."},
      {"text": "Inhibiting presynaptic ACh release and blocking postsynaptic nicotinic receptors", "explanation": "This is correct. The neuromuscular blockade is a curare-like effect that results from 1) inhibiting presynaptic acetylcholine release (by competing with Ca2+) and 2) decreasing sensitivity of postsynaptic nicotinic receptors."},
      {"text": "Destroying cochlear hair cells and damaging the optic nerve", "explanation": "This is incorrect. This describes ototoxicity and streptomycin neurotoxicity, not neuromuscular blockade."},
      {"text": "Accumulating in the proximal tubule and causing ATN", "explanation": "This is incorrect. This describes nephrotoxicity."},
      {"text": "Binding to pulmonary surfactant and causing myopathy", "explanation": "This is incorrect. This mixes daptomycin's contraindication and its adverse effect."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0028.jpg"
  },
  {
    "id": 38,
    "category": "Aminoglycosides: Adverse Effects (Streptomycin)",
    "questionText": "A 48-year-old male on a multi-drug regimen for MDR-TB, including streptomycin, complains of a new 'blind spot' in his central vision. This symptom is most likely due to which specific toxicity associated with streptomycin?",
    "options": [
      {"text": "Cochlear toxicity", "explanation": "This is incorrect. Cochlear toxicity would cause tinnitus or hearing loss."},
      {"text": "Vestibular toxicity", "explanation": "This is incorrect. Vestibular toxicity would cause vertigo or ataxia."},
      {"text": "Optic nerve toxicity (Scotoma)", "explanation": "This is correct. In addition to the class toxicities, streptomycin is associated with specific neurotoxicities, including optic nerve toxicity, which can present as scotomas (blind spots)."},
      {"text": "Peripheral neuritis", "explanation": "This is incorrect. Peripheral neuritis, also a streptomycin toxicity, would present with paresthesias (numbness/tingling) of the face and hands, not a blind spot."},
      {"text": "Neuromuscular blockade", "explanation": "This is incorrect. This would present as acute muscle weakness."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0029.jpg"
  },
  {
    "id": 39,
    "category": "Aminoglycosides: Adverse Effects (Neomycin)",
    "questionText": "A 22-year-old male uses an over-the-counter 'triple antibiotic' ointment for a small cut. Two days later, the area is red, vesicular, and intensely pruritic. This contact hypersensitivity reaction (allergic dermatitis) is most frequently caused by which component of the ointment?",
    "options": [
      {"text": "Bacitracin", "explanation": "This is incorrect. While possible, neomycin is the most frequent contact allergen in these preparations."},
      {"text": "Polymyxin B", "explanation": "This is incorrect. Polymyxin B is less commonly the cause of the allergy."},
      {"text": "Neomycin", "explanation": "This is correct. Neomycin, used topically, is a frequent cause of allergic contact dermatitis (hypersensitivity)."},
      {"text": "Gentamicin", "explanation": "This is incorrect. Gentamicin is not typically in standard triple antibiotic ointment; neomycin is."},
      {"text": "Clotrimazole", "explanation": "This is incorrect. Clotrimazole is an antifungal, not a component of this ointment."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L124_page-0024.jpg"
  },
  {
    "id": 40,
    "category": "Aminoglycosides: Drug Interactions",
    "questionText": "A 78-year-old female is receiving IV gentamicin for a cUTI and IV furosemide for heart failure exacerbation. The physician must be vigilant in monitoring this patient for an increased risk of which additive toxicities?",
    "options": [
      {"text": "Myopathy and seizures", "explanation": "This is incorrect. These are toxicities of daptomycin and imipenem, respectively."},
      {"text": "Nephrotoxicity and ototoxicity", "explanation": "This is correct. Loop diuretics (like furosemide) are ototoxic and nephrotoxic. Aminoglycosides are also nephrotoxic and ototoxic. Using them concomitantly significantly increases the risk of both toxicities."},
      {"text": "Neuromuscular blockade", "explanation": "This is incorrect. The additive risk with furosemide is not neuromuscular blockade."},
      {"text": "Biliary sludge and kernicterus", "explanation": "This is incorrect. These are risks associated with ceftriaxone."},
      {"text": "Disulfiram-like reaction", "explanation": "This is incorrect. This is associated with cefotetan."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L124_page-0030.jpg"
  }
];